At a glance
ClinicalIndex Comparison Record- ✓Probable or possible Alzheimer's disease diagnosis
- ✓Disruptive agitated behaviors such as irritability, aggression, uncooperativeness, or pacing
- ✓No current hypotension
- ✓Not currently taking alpha-1-blockers
- ✕Unstable angina, recent myocardial infarction, or high-degree AV block
- ✕Preexisting hypotension (systolic <110 mmHg) or orthostatic hypotension
- ✕Chronic renal or hepatic failure or unstable medical condition
- ✕Current treatment with prazosin or other alpha-1-blockers
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Alzheimer's in Long-Term Care--Treatment for Agitation
In Brief
A clinical study evaluating prazosin and placebo (inert substance) for Alzheimer Disease and Psychomotor Agitation. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.
Study Details
Timeline
Interventions
Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime. Duration was 8 weeks.
Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.